Role of smooth muscle cell mineralocorticoid receptor in vascular tone

Pflugers Archiv European Journal of Physiology

Volumn 467, Issue 8, 2015, Pages 1643-1650

  Tarjus, Antoine ^a,b   Belozertseva, Ekaterina ^c   Louis, Huguette ^c   El Moghrabi, Soumaya ^a,b   Labat, Carlos ^c   Lacolley, Patrick ^c   Jaisser, Frédéric ^a,b,d   Galmiche, Guillaume ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d CHU NANCY BRABOIS   (France)

Author keywords

Aldosterone; Aorta; Contractility; Relaxation; Transgenic mice

Indexed keywords

ACETYLCHOLINE; CAFFEINE; CALCIUM ION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDOMETACIN; MINERALOCORTICOID RECEPTOR; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN PHOSPHATASE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE; NOS3 PROTEIN, MOUSE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL SPECIFICITY; CONTROLLED STUDY; HEART CONTRACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; ABDOMINAL AORTA; ANIMAL; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; EXCITATION CONTRACTION COUPLING; GENETICS; KNOCKOUT MOUSE; METABOLISM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; AORTA, ABDOMINAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATION CONTRACTION COUPLING; IN VITRO TECHNIQUES; MALE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN-LIGHT-CHAIN KINASE; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, MINERALOCORTICOID; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84937817023     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-014-1616-x     Document Type: Article

References (23)

1. Alvarez Y, Briones AM, Balfagon G, Alonso MJ, Salaices M (2005) Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J Hypertens 23:767–777
2. Barrett KV, McCurley AT, Jaffe IZ (2013) Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol 40:902–909. doi:10.1111/1440-1681.12125
3. Birukova AA, Smurova K, Birukov KG, Kaibuchi K, Garcia JG, Verin AD (2004) Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. Microvasc Res 67:64–77
4. Chataigneau T, Feletou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM (1999) Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126:219–226. doi:10.1038/sj.bjp.0702300
5. DeLano FA, Schmid-Schonbein GW (2004) Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 11:69–78
6. Duprez DA (2010) Is vascular stiffness a target for therapy? Cardiovasc Drugs Ther 24:305–310. doi:10.1007/s10557-010-6250-z
7. Feng J, Ito M, Nishikawa M, Okinaka T, Isaka N, Hartshorne DJ, Nakano T (1999) Dephosphorylation of distinct sites on the 20 kDa myosin light chain by smooth muscle myosin phosphatase. FEBS Lett 448:101–104
8. Funder JW (2013) Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 6:129–138. doi:10.2147/ibpc.S13783
9. Funder JW, Mihailidou AS (2009) Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 301:2–6. doi:10.1016/j.mce.2008.10.029
10. Galmiche G, Labat C, Mericskay M, Aissa KA, Blanc J, Retailleau K, Bourhim M, Coletti D, Loufrani L, Gao-Li J, Feil R, Challande P, Henrion D, Decaux JF, Regnault V, Lacolley P, Li Z (2013) Inactivation of serum response factor contributes to decrease vascular muscular tone and arterial stiffness in mice. Circ Res 112:1035–1045. doi:10.1161/circres.113.301076
11. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F (2014) Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 63:520–526. doi:10.1161/hypertension.113.01967
12. Hirano K (2007) Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol Sci 104:109–115
13. Isotani E, Zhi G, Lau KS, Huang J, Mizuno Y, Persechini A, Geguchadze R, Kamm KE, Stull JT (2004) Real-time evaluation of myosin light chain kinase activation in smooth muscle tissues from a transgenic calmodulin-biosensor mouse. Proc Natl Acad Sci U S A 101:6279–6284. doi:10.1073/pnas.0308742101
14. Levy DG, Rocha R, Funder JW (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89:2736–2740. doi:10.1210/jc.2003-032149
15. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ (2012) Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18:1429–1433. doi:10.1038/nm.2891
16. Mendelsohn ME (2005) In hypertension, the kidney is not always the heart of the matter. J Clin Invest 115:840–844. doi:10.1172/jci24806
17. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41:19–26
18. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P (2006) Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 7:31–39. doi:10.3317/jraas.2006.004
19. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F (2010) The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J: Off Publ Fed Am Soc Exp Biol 24:2454–2463. doi:10.1096/fj.09-147926
20. Nguyen Dinh Cat A, Jaisser F (2012) Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 21:147–156. doi:10.1097/mnh.0b013e32834fb25b
21. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ (2014) Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 34:355–364. doi:10.1161/atvb.113.302854
22. Shimizu H, Ito M, Miyahara M, Ichikawa K, Okubo S, Konishi T, Naka M, Tanaka T, Hirano K, Hartshorne DJ et al (1994) Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J Biol Chem 269:30407–30411
23. Takeda Y (2009) Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res 32:321–324. doi:10.1038/hr.2009.29